MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers

Cell Cycle

Volumn 12, Issue 9, 2013, Pages 1385-1394

  Qian, Xu ^a   Yu, Jing ^a   Yin, Yu ^a,b   He, Jun ^c   Wang, Lin ^a   Li, Qi ^a   Zhang, Lou Qian ^a   Li, Chong Yong ^a   Shi, Zhu Mei ^a   Xu, Qing ^a   Li, Wei ^a   Lai, Li Hui ^d   Liu, Ling Zhi ^c   Jiang, Bing Hua ^a,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Chemotherapy; IGF IR; MicroRNA 143; Tumorigenesis

Indexed keywords

MICRORNA 143; OXALIPLATIN; SOMATOMEDIN C RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER STAGING; CELL PROLIFERATION; CHEMOSENSITIZATION; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MIGRATION INHIBITION;

EID: 84877117382     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.24477     Document Type: Article

References (51)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108; PMID:15761078; http://dx.doi.org/10.3322/ canjclin.55.2.74.
2. Walsh JM, Terdiman JP. Colorectal cancer screening: scientific review. JAMA 2003; 289:1288-96; PMID:12633191; http://dx.doi.org/10.1001/jama.289.10. 1288.
3. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet 2010; 375:1030-47; PMID:20304247; http://dx.doi.org/ 10.1016/S0140-6736(10)60353-4.
4. Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, et al. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS ONE 2011; 6:e18286; PMID:21464941; http://dx.doi.org/10.1371/journal.pone.0018286.
5. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136:215-33; PMID:19167326; http://dx.doi.org/10.1016/j.cell.2009.01.002.
6. Hermeking H. p53 enters the microRNA world. Cancer Cell 2007; 12:414-8; PMID:17996645; http://dx.doi.org/10.1016/j.ccr.2007.10.028.
7. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103:2257-61; PMID:16461460; http://dx.doi.org/10. 1073/pnas.0510565103.
8. Lichter P. All you need is a Mir-acle: the role of nontranslated RNAs in the suppression of B cell chronic lymphocytic leukemia. Cancer Cell 2010; 17:3-4; PMID:20129242; http://dx.doi.org/10.1016/j.ccr.2009.12.029.
9. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141:672-5; PMID:18318758; http://dx.doi.org/10.1111/j.1365-2141.2008.07077.x.
10. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105:10513-8; PMID:18663219; http://dx.doi.org/10.1073/pnas.0804549105.
11. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18:997-1006; PMID:18766170; http://dx.doi.org/10. 1038/cr.2008.282.
12. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110:13-21; PMID:18589210; http://dx.doi.org/10.1016/j.ygyno.2008.04.033.
13. Ahmed FE, Amed NC, Vos PW, Bonnerup C, Atkins JN, Casey M, et al. Diagnostic microRNA markers to screen for sporadic human colon cancer in blood. Cancer Genomics Proteomics 2012; 9:179-92; PMID:22798503.
14. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009; 58:1375-81; PMID:19201770; http://dx.doi.org/10.1136/gut.2008.167817.
15. Bihrer V, Waidmann O, Friedrich-Rust M, Forestier N, Susser S, Haupenthal J, et al. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS ONE 2011; 6:e26971; PMID:22066022; http://dx.doi.org/10.1371/journal.pone.0026971.
16. Morimura R, Komatsu S, Ichikawa D, Takeshita H, Tsujiura M, Nagata H, et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer 2011; 105:1733-40; PMID:22045190; http://dx.doi.org/10.1038/bjc.2011.453.
17. Liu J, Gao J, Du Y, Li Z, Ren Y, Gu J, et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 2012; 131:683-91; PMID:21913185.
18. Qu H, Xu W, Huang Y, Yang S. Circulating miRNAs: promising biomarkers of human cancer. Asian Pac J Cancer Prev 2011; 12:1117-25; PMID:21875254.
19. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC. Circulating microRNA expression profiles in early stage non-small cell lung cancer. Int J Cancer 2012; 130:1378-86; PMID:21544802.
20. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010; 101:2087-92; PMID:20624164; http://dx.doi.org/10.1111/j.1349-7006.2010.01650.x.
21. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, et al. Serum microRNA signatures identified in a genomewide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010; 28:1721-6; PMID:20194856; http://dx.doi.org/10.1200/JCO.2009.24.9342.
22. Dong X, Javle M, Hess KR, Shroff R, Abbruzzese JL, Li D. Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology 2010; 139(73 e1-3):464-73, e1-3; PMID:20416304; http://dx.doi.org/10.1053/j.gastro.2010.04.042.
23. La Rocca G, Badin M, Shi B, Xu SQ, Deangelis T, Sepp-Lorenzinoi L, et al. Mechanism of growth inhibition by MicroRNA 145: the role of the IGF-I receptor signaling pathway. J Cell Physiol 2009; 220:485-91; PMID:19391107; http://dx.doi.org/10.1002/jcp.21796.
24. Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2012; 61:33-42; PMID:21813472; http://dx.doi.org/10.1136/gutjnl-2011-300178.
25. Jiang L, Liu X, Chen Z, Jin Y, Heidbreder CE, Kolokythas A, et al. MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J 2010; 432:199-205; PMID:20819078; http://dx.doi.org/10.1042/BJ20100859.
26. Flanigan SA, Pitts TM, Eckhardt SG, Tentler JJ, Tan AC, Thorburn A, et al. The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. Clin Cancer Res 2010; 16:5436-46; PMID:20943761; http://dx.doi.org/10.1158/1078-0432.CCR-10-2054.
27. Zhang C, Wang J, Gu H, Zhu D, Li Y, Zhu P, et al. Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials. Oncol Lett 2012; 3:831-8; PMID:22741002.
28. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75:843-54; PMID:8252621; http://dx.doi.org/10.1016/0092-8674(93)90529-Y.
29. Xia H, Cheung WK, Ng SS, Jiang X, Jiang S, Sze J, et al. Loss of brain-enriched miR-124 microRNA enhances stem-like traits and invasiveness of glioma cells. J Biol Chem 2012; 287:9962-71; PMID:22253443; http://dx.doi.org/ 10.1074/jbc.M111.332627.
30. Xia H, Ooi LL, Hui KM. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. PLoS ONE 2012; 7:e44206; PMID:22962603; http://dx.doi.org/10.1371/journal.pone. 0044206.
31. Noman MZ, Buart S, Romero P, Ketari S, Janji B, Mari B, et al. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res 2012; 72:4629-41; PMID:22962263; http://dx.doi.org/10.1158/0008-5472.CAN-12-1383.
32. Fang R, Xiao T, Fang Z, Sun Y, Li F, Gao Y, et al. MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene. J Biol Chem 2012; 287:23227-35; PMID:22593586; http://dx.doi.org/10.1074/jbc.M112.373084.
33. Kent OA, Fox-Talbot K, Halushka MK. RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets. Oncogene 2012; Epub Ahead of Print; PMID:22751122; http://dx.doi.org/10.1038/onc.2012.266.
34. Gregersen LH, Jacobsen A, Frankel LB, Wen J, Krogh A, Lund AH. MicroRNA-143 down-regulates Hexokinase 2 in colon cancer cells. BMC Cancer 2012; 12:232; PMID:22691140; http://dx.doi.org/10.1186/1471-2407-12-232.
35. Shi ZM, Wang J, Yan Z, You YP, Li CY, Qian X, et al. MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1. PLoS ONE 2012; 7:e32709; PMID:22442669; http://dx.doi.org/10.1371/journal.pone.0032709.
36. Pan J, Fauzee NJ, Wang YL, Sheng YT, Tang Y, Wang JQ, et al. Effect of silencing PARG in human colon carcinoma LoVo cells on the ability of HUVEC migration and proliferation. Cancer Gene Ther 2012; 19:715-22; PMID:22918473; http://dx.doi.org/10.1038/cgt.2012.48.
37. Hart LS, Dolloff NG, Dicker DT, Koumenis C, Christensen JG, Grimberg A, et al. Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle 2011; 10:2331-8; PMID:21720213; http://dx.doi.org/10.4161/cc.10.14.16418.
38. Zhao D, Bakirtzi K, Zhan Y, Zeng H, Koon HW, Pothoulakis C. Insulin-like growth factor-1 receptor transactivation modulates the inflammatory and proliferative responses of neurotensin in human colonic epithelial cells. J Biol Chem 2011; 286:6092-9; PMID:21212273; http://dx.doi.org/10.1074/jbc.M110. 192534.
39. Fang J, Zhou Q, Liu LZ, Xia C, Hu X, Shi X, et al. Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis 2007; 28:858-64; PMID:17071632; http://dx.doi.org/10.1093/carcin/ bgl205.
40. Yuen JS, Akkaya E, Wang Y, Takiguchi M, Peak S, Sullivan M, et al. Validation of the type 1 insulinlike growth factor receptor as a therapeutic target in renal cancer. Mol Cancer Ther 2009; 8:1448-59; PMID:19509240; http://dx.doi.org/10.1158/1535-7163.MCT-09-0101.
41. Poulaki V, Mitsiades CS, McMullan C, Sykoutri D, Fanourakis G, Kotoula V, et al. Regulation of vascular endothelial growth factor expression by insulinlike growth factor I in thyroid carcinomas. J Clin Endocrinol Metab 2003; 88:5392-8; PMID:14602779; http://dx.doi.org/10.1210/jc.2003-030389.
42. Patel BB, Gupta D, Elliott AA, Sengupta V, Yu Y, Majumdar AP. Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res 2010; 30:319-25; PMID:20332435.
43. Patel BB, Sengupta R, Qazi S, Vachhani H, Yu Y, Rishi AK, et al. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer 2008; 122:267-73; PMID:17918158; http://dx.doi.org/10.1002/ijc.23097.
44. Neugut AI, Becker DJ, Insel BJ, Hershman DL. Uptake of oxaliplatin and bevacizumab for treatment of node-positive and metastatic colon cancer. J Oncol Pract 2012; 8:156-63; PMID:22942809; http://dx.doi.org/10.1200/JOP.2011.000371.
45. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010; 50:298-301; PMID:20146939; http://dx.doi.org/10.1016/j. ymeth.2010.01.032.
46. Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci USA 2010; 107:21098-103; PMID:21078976; http://dx.doi.org/10.1073/pnas.1015541107.
47. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33:e179; PMID:16314309; http://dx.doi.org/10.1093/nar/gni178.
48. Wang X. A PCR-based platform for microRNA expression profiling studies. RNA 2009; 15:716-23; PMID:19218553; http://dx.doi.org/10.1261/rna.1460509.
49. Jing Y, Liu LZ, Jiang Y, Zhu Y, Guo NL, Barnett J, et al. Cadmium increases HIF-1 and VEGF expression through ROS, ERK, and AKT signaling pathways and induces malignant transformation of human bronchial epithelial cells. Toxicol Sci 2012; 125:10-9; PMID:21984483; http://dx.doi.org/10.1093/toxsci/ kfr256.
50. Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y, et al. A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J Mol Cell Biol 2013; 5:3-13; PMID:22935141.
51. Zhang C, Hao L, Wang L, Xiao Y, Ge H, Zhu Z, et al. Elevated IGFIR expression regulating VEGF and VEGF-C predicts lymph node metastasis in human colorectal cancer. BMC Cancer 2010; 10:184; PMID:20459642; http://dx.doi.org/10. 1186/1471-2407-10-184.